Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations

Thrombosis and Haemostasis

Volumn 86, Issue 6, 2001, Pages 1459-1465

  Rastegar Lari, G ^a   Ajzenberg, N ^a   Ribba, A S ^a   Vereycken Holler, V ^a   Legendre, P ^a   Villoutreix, B O ^a   Meyer, D ^a   Baruch, D ^a  

^a INSERM   (France)

Author keywords

Heparin; Von Willebrand disease; Von Willebrand factor

Indexed keywords

AGAROSE; HEPARIN; MONOCLONAL ANTIBODY I 125; VON WILLEBRAND FACTOR;

ARTICLE; BINDING KINETICS; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG BINDING; GENE MUTATION; HUMAN; MUTANT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FOLDING; STRUCTURE ANALYSIS; VON WILLEBRAND DISEASE;

EID: 0035655538     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616749     Document Type: Article

References (36)

1. Biochemistry and genetics of von Willebrand factor
2. Von Willebrand disease: A database of point mutations, insertions, and deletions
3. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function
4. The Arg552Cys mutation within the A1 loop of von Willebrand Factor (VWF) induces an abnormal folding with a loss-of-function resulting in a 2A-like phenotype. Study of ten patients and of mutated recombinant VWF
5. Laboratory diagnosis of von Willebrand disease
6. Von Willebrand factor binding to heparin in various types of von Willebrand disease
7. A heparin-binding domain of human von Willebrand factor
8. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites
9. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor
10. Substructure of human von Willebrand factor: Proteolysis by V-8 and characterization of two functional domains
11. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin
12. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis
13. Defects in type IIA von Willebrand disease: A cysteine 509 to arginine substitution in the mature von Willebrand factor disrupts a disulphide loop involved in the interaction with platelet glycoprotein Ib-IX
14. Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease
15. Molecular basis of von Willebrand disease type-IIB - Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein-Ib binding sequences
16. The molecular defect in type-IIB von Willebrand disease - Identification of four potential missense mutations within the putative GPIb binding domain
17. Recombinant von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin
18. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets
19. Identification of two mutations (Arg 611 Cys and Arg 611 His) in the A1 loop responsible for type 2 von Willebrand disease with decreased platelet dependent function of von Willebrand factor
20. Domains involved in multimer assembly of von Willebrand factor (VWF). Multimerization is independent of dimerization
21. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib
22. Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695
23. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation
24. A new type 2M ("type B") VWD mutation (G1324A) also at position 561 of the mature VWF subunit
25. Effects of different amino-acid substitutions in the leucine 649-proline 708 segment of recombinant von Willebrand factor
26. Leu 697 → Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease
27. Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor
28. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries
29. A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease
30. Interaction of von Willebrand factor with human platelets in the plasma milieu
31. Binding of heparin fractions to von Willebrand factor: Effect of molecular weight and affinity for antithrombin III
32. Heparin binding assay of von Willebrand factor (VWF) in plasma milieu - Evidence of the importance of the multimerization degree of VWF
33. Localization of von Willebrand Factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-Alanine scanning mutagenesis
34. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: A reappraisal using phenotypes genotypes and molecular modelling
35. Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab
36. Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib